The systemic therapies have been approved for advanced HCC, such as tyrosine kinase inhibitor (TKI, sorafenib and lenvatinib) and combinations of immunotherapies with vascular endothelial growth factor (VEGF)A monoclonal antibodies [4]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.